Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by GW&K Investment Management LLC

GW&K Investment Management LLC grew its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 35.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 252,240 shares of the company's stock after purchasing an additional 65,635 shares during the quarter. GW&K Investment Management LLC owned approximately 0.40% of Vera Therapeutics worth $6,059,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Huntington National Bank acquired a new position in Vera Therapeutics in the fourth quarter worth about $26,000. GF Fund Management CO. LTD. bought a new position in Vera Therapeutics during the 4th quarter worth approximately $56,000. Summit Investment Advisors Inc. grew its position in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Vera Therapeutics by 1,779.1% in the 1st quarter. GAMMA Investing LLC now owns 8,287 shares of the company's stock valued at $199,000 after acquiring an additional 7,846 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in shares of Vera Therapeutics during the 4th quarter valued at approximately $249,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on VERA shares. Cantor Fitzgerald decreased their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Wedbush lowered their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $65.00.

Vera Therapeutics Stock Performance

Shares of VERA stock traded down $0.07 during trading hours on Friday, reaching $21.81. The stock had a trading volume of 946,343 shares, compared to its average volume of 938,498. The firm has a market capitalization of $1.39 billion, a PE ratio of -7.27 and a beta of 1.19. The firm has a 50-day simple moving average of $22.85 and a 200-day simple moving average of $26.09. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a debt-to-equity ratio of 0.10, a current ratio of 27.68 and a quick ratio of 27.68.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, Director Patrick G. Enright bought 209,393 shares of the stock in a transaction that occurred on Monday, June 23rd. The shares were purchased at an average cost of $20.87 per share, for a total transaction of $4,370,031.91. Following the transaction, the director directly owned 3,569,522 shares in the company, valued at $74,495,924.14. The trade was a 6.23% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.30% of the stock is owned by company insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.